Advanced KRAS G12D-Mutant Solid Tumors research hub

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

This study is testing a new drug, VS-7375, for advanced solid cancers with a specific gene change called KRAS G12D. Researchers want to see if it's safe and helps shrink tumors, both alone and with other standard cancer treatments. It's an early-stage trial looking at how the drug works.